ESI/APAVE/ONET
1.12.2021 18:30:04 CET | Business Wire | Press release
Regulatory News:
This replaces the announcement made at 3:15 PM on December 1st due to the following corrections: Last quote was cancelled.
Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India
A collaboration supported by the EDF Group and based on French complementarity and excellence.
Apave, ESI Group and Onet Technologies have formalized, at the WNE (World Nuclear Exhibition) 2021, their collaboration, through the MINS (Make in India Nuclear supply chain Support) alliance, to build a common value proposition in order to respond to the project to create six EPR reactors on the Jaitapur site in western India.
Philippe Maillard, CEO of APAVE Group, Emmanuel Leroy, EVP Product, Innovation & Industry Solutions of ESI Group and Alain Gauvin, CEO of ONET Technologies, signed today at WNE 2021, with the participation of Xavier Ursat, Group Senior Executive Vice President, New Nuclear Projects and Engineering, a joint declaration of intent structuring the MINS alliance, thus combining their skills on the outstanding Indian EPR market at the Jaitapur site.
A unique Indian project
In April 2021, EDF submitted a binding technical and commercial offer to NCPIL (Nuclear Power Corporation of India Limited - India's state-owned nuclear power company) for the construction of six EPR (pressurized water reactor) reactors in India, at the Jaitapur site in the state of Maharashtra, whose capital is Bombay, the country's economic and commercial center. With an installed capacity of 9.6 GW, this plant would be the most powerful in the world. It would produce up to 75 TWh per year and cover the annual consumption of 70 million Indian households, while avoiding the emission of about 80 million tons of CO2 per year.
A unique French alliance based on complementary expertise
Based on more than forty years of experience in the nuclear sector, APAVE, ESI Group and ONET Technologies have combined their skills and know-how: in nuclear engineering for ONET Technologies, in compliance with regulatory and non-regulatory safety and security requirements for APAVE, and in virtual prototyping capabilities for ESI Group, in order to put them at the service of the project.
This combination enables the MINS alliance to offer a complete range of services ("one-stop shop" approach) to Indian manufacturers, constructors, and assemblers, from assistance in the design of systems and equipment to commissioning, including support in manufacturing methods and monitoring, numerical simulations to support component sizing, and quality and regulatory controls.
About the Apave Group
Apave is an international group with over 150 years of experience in risk management. An independent company with a turnover of €881M in 2019, Apave currently has 12,600 employees, 130 agencies in France, 170 training sites in France and abroad and 18 testing centres. Apave has an international presence in over 45 countries. Nearly 500,000 customers already place their trust in Apave in France and abroad. www.apave.com
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris. www.esi-group.com
About Onet Technologies
Onet Technologies has been in the market for some 40 years and specializes in reactor engineering and maintenance, decommissioning and nuclear waste treatment, as well as operator services for major players in the nuclear sector. Safety and security culture, skills management and operational performance are at the heart of the services delivered by Onet Technologies for each of its clients. The company currently employs nearly 2,900 engineers and technicians and has established a number of long-term international partnerships. www.onet.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005922/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom